Invivogen
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 22, 2027The maintenance fee for Pro-Cyclic Dinucleotides and Pro-Cyclic Dinucleotide Conjugates for Cytokine Induction (US 11,730,817) comes due Feb 22, 2027. Unpaid by Aug 23, 2027, it lapses early.
- 1 fee due Sep 29, 2027The maintenance fee for Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists (US 9,295,732) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,435,777 | CPG-free gene for a new secreted reporter protein In force · From the USPTO record | In force | From the USPTO record | |
| US 9,295,732 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists In force · From the USPTO record | In force | From the USPTO record | |
| US 9,458,184 | Compositions of TLR7 and/or TLR8 agonists conjugated to lipids In force · From the USPTO record | In force | From the USPTO record | |
| US 9,567,336 | Conjugated TLR7 and/or TLR8 and TLR2 agonists In force · From the USPTO record | In force | From the USPTO record | |
| US 10,705,076 | Anti-HLA monoclonal chimeric immunoglobulin, method and kit implementing such a monoclonal chimeric immunoglobulin In force · From the USPTO record | In force | From the USPTO record | |
| US 9,637,538 | Anti-HLA monoclonal chimeric immunoglobulin, process and kit employing such a monoclonal chimeric immunoglobulin In force · From the USPTO record | In force | From the USPTO record | |
| US 11,730,817 | Pro-Cyclic Dinucleotides and Pro-Cyclic Dinucleotide Conjugates for Cytokine Induction In force · High confidence | In force | High confidence |
Also on record, not counted in the 7: 4 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 no status recorded